In May 2024, Knight entered into an agreement with Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Ironshore Therapeutics, Inc. (now part of Collegium Pharmaceutical, Inc.; ...

Our latest article Designing for Neurodivergence explores the main principles for supporting ADHD and autism in the built ...